In late June, Bruce Power joined forces with Isotopen Technologien München (ITM) to examine the production of the radioisotope Lutetium-177 at the Bruce Power site. Lu-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumours and prostate cancer. The medical-grade radioisotope is used to destroy cancer cells while leaving healthy cells unaffected. According to the company, the Bruce Power site has the ability to meet global supply needs through 2064, which is the lifespan of the station after refurbishment. “By developing innovative ways to generate these radioisotopes, we help ensure that the medical community has access to […] Read more about Bruce Power to produce Lutetium-177 for cancer therapy